ProCE Banner Activity

CE / CME

Conference to Clinic: Recent Advances in Biomarker-Driven Treatment of GI Cancers

In this interactive webcast, a dynamic expert panel discusses the latest data on the use of biomarker-driven treatments for patients with gastrointestinal cancers.

ABIM MOC : maximum of 1.00 Medical Knowledge MOC point(s)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 10, 2021

Expiration: August 09, 2022

No longer available for credit.

Share

Faculty

Allison M. Cushman-Vokoun

Allison M. Cushman-Vokoun, MD, PhD

Associate Professor
Department of Pathology and Microbiology
University of Nebraska Medical Center
Medical Director
Molecular Diagnostics Laboratory and Human Genetics Laboratory
Department of Pathology and Microbiology
Nebraska Medicine
Omaha, Nebraska

John L. Marshall

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

Merck Sharp & Dohme Corp.

Target Audience

This educational program is intended for oncologists, pathologists, and other healthcare professionals involved in precision testing and treatment of GI malignancies.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss the expanding role and increasing importance of biomarker testing that can guide the selection of therapy for patients with GI malignancies in the era of precision oncology
  • Describe current and emerging testing methods/tools for identifying actionable biomarkers in patients with GI malignancies
  • Analyze data from clinical trials of precision therapies in select GI malignancies and use this information to guide evidence-based care
  • Become familiar with the design of ongoing clinical trials for novel biomarker-driven treatment strategies in GI malignancies, and counsel appropriate patients about availability and participation

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Allison M. Cushman-Vokoun, MD, PhD

Associate Professor
Department of Pathology and Microbiology
University of Nebraska Medical Center
Medical Director
Molecular Diagnostics Laboratory and Human Genetics Laboratory
Department of Pathology and Microbiology
Nebraska Medicine
Omaha, Nebraska

Allison M. Cushman-Vokoun, MD, PhD, FCAP, has disclosed that she has received other financial or material support from ThermoFisher Scientific.

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John L. Marshall, MD, has disclosed that he has received consulting fees from Bayer, Caris, Indivumed, Daiichi Sankyo, and Taiho; salary from Indivumed; and fees for non-CME services from Bayer, Daiichi Sankyo, Merck, Pfizer, and Taiho.

Staff Disclosure

Staff

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 10, 2021, through August 09, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to optimally integrate current and emerging biomarkers to guide treatment decisions for patients with select GI malignancies.